Over one million people in sub-Saharan Africa now access HIV treatment, and as the prognosis of lifeexpectancy on antiretroviral therapy (ART) improves, the central question that arises for governments, civil society and the private sector must be: how will we pay for the health-care costs? [1] . As millions more will need access to treatment over the coming decade, finding an answer to this question is a moral and economic imperative. This paper critically evaluates the need to provide effective treatment, prevention and care for HIV over the long term. Compelling evidence and moral argument suggest that the right combination of treatment and prevention policies, bolstered by grassroots mobilization and effective treatment literacy campaigns, can prevent new infections, save lives and mitigate the impact of the epidemic. More than 25 years of research and experience has clarified that treatment is integral to effective AIDS programming. As the Harvard Consensus Statement [2] suggested, this is particularly true in countries worst affected by the epidemic where prevention efforts have failed to halt the spread of the disease.
The governments of Brazil and to a lesser extent Thailand have acted with urgency and foresight in this regard, documenting noteworthy results over the past decade. When supplemented by data from these countries, South Africa's HIV epidemic and its antiretroviral roll-out provide instructive global templates for governments, international agencies, the private sector and activists. The scale of our epidemic, the political responses, the epidemiological evidence and the outcomes data are lessons for countries where there is only a low-level epidemic at present [3] .
The roots of the HIV/AIDS epidemic in South Africa are embedded in structures of social inequality that run deep into a history of exploitation and oppression. Colonialism, apartheid, migrant labour, rural labour reservoirs, unequal social investment and the social, political, economic and cultural inequality of women have all created structural vulnerability to HIV infection [4] . The costs measured in lives lost, political and social conflict, poor governance and new infections (all the result of delays in treatment as well as AIDS denialism) are high. In light of these systemic fault lines and the growth of the epidemic, the investment needed to provide universal ARTand to halt the spread of HIV in South Africa will be substantial. Nonetheless, important gains have been made. Community level health facilities in South Africa's Western Cape and Lusikisiki, a poor rural municipality in the Eastern Cape, have documented encouraging treatment and adherence results. South Africa's example suggests that even after tragic mistakes have been made, collective action, evidence-informed programmes, and sustained investment can still save lives and mitigate the epidemic.
It remains to be seen how pervasive and destructive AIDS denialism will continue to be in South Africa. For now, there are encouraging signs from members of South African leadership. But the costs thus far have been substantial. Nattrass [5] provided an overview of the country's progression of AIDS denialism. The most unfortunate ramification, the author noted, has been 'the erosion of the authority of science and of scientific regulation of medicine in South Africa. . .. Not only does this pose serious problems for effective and safe governance within the health sector, but it threatens the health and lives of the many AIDS patients who are ill-equipped to judge the relative efficacy of antiretroviral and alternative therapies'.
To conclude, this paper proposes a series of actions that can be taken by civil society, governments, international agencies and the private sector to share the burden of the epidemic. In doing so, we can provide relief to millions, and save and improve the economic, political and social infrastructures that are at stake.
South Africa: the social costs of prevention-only programmes, [1990] [1991] [1992] [1993] [1994] [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] South Africa has among the highest levels of HIV in the world. Since the early 1990s, antenatal clinics have witnessed a relentless increase in the number of HIVinfected women. In 1990, the National HIV Syphilis Antenatal Sero-Prevalence Survey reported a 0.7% rate of infection. Brazil and Thailand reported comparable rates of HIV infection at that time. In Thailand, prevalence rates among women attending prenatal clinics were reported at 0.89% in 1989 [6] . In 1996, Brazil's incidence rate stabilized at approximately 14 cases per 100 000 (less than 0.01%) [7] . But in South Africa, by 2005, the number of pregnant women with HIV at public health facilities had increased to over 30% [8] . Country-wide, adult HIV prevalence (the percentage of the population currently infected) is now estimated at 15.6%. And between the ages of 25 and 34 years, more than one in five individuals is infected with HIV [9] .
Among youth, young women continue to bear a disproportionate share of the burden. Approximately 15.5% of women between 15 and 24 years of age are HIV positive, in contrast to a 4.8% prevalence among young men of the same age [10] . This imbalance is largely the result of the economic dependence of younger women on older men, who provide commodities, money or care in exchange for companionship. Such norms are clear evidence of the interrelationship between socioeconomic status and AIDS. Many women cannot protect themselves; they find themselves economically and socially dependent on men, their families, or the state.
The drivers of the epidemic continue to fuel infection and death rates of able-bodied adults of peak working and reproductive age, in both private and public sector capacities. Among teachers in South Africa aged 25-34 years, prevalence has reached 21.4%, and in 2004 1.1% of all educators died as a result of AIDS-related illnesses [11, 12] . This trend, coupled with the increasing number of AIDS orphans (now reported to be over 1.2 million country-wide) places serious strain on communities, social security and the educational system [13] . Preva-Unfortunately, South Africa's burden is now two-fold: while the HIV epidemic of the early nineties continues with more than 500 000 new infections occurring in 2005, it is now super-imposed with a second, more potent epidemic of AIDS. This second epidemic is accompanied by serious increases in morbidity and mortality. In a speech given on 1 December 2006, the South African Deputy President, Phumzile MlamboNgcuka, cautioned South Africans about the destructive implications of the HIV/AIDS epidemic: 'As South Africans we must be proud of the gains that democracy has brought and can bring to future generations. But we are also concerned that the HIV and AIDS pandemic can erode these gains. . .. Many parents are dying prematurely resulting in an increased number of orphans. Many of us experience these realities in our day to day life' [15] . The Deputy Minister of Health, Nozizwe Madlala Routledge, has expressed similar concerns publicly.
The cumulative impact of the HIV/AIDS epidemic has been a fundamental change in the generational life patterns of South African society. Figure 1 The message is very clear: currently, more individuals in South Africa die between the ages of 20 and 40 years than between the ages of 60 and 80 years. Women aged between 24 and 44 years are disproportionately affected by AIDS-related deaths. These deaths occur during the peak years of an individual's economic and child-rearing productivity, reshaping the fabric of society. A recent report from the Office of the Presidency expressed this in frank terms: '[T]here is clearly not only a pandemic in silent attack, but its fatal impact is starting to express itself palpably in both morbidity and mortality. The most affected in this regard are able-bodied citizens in the prime of their lives. These would most likely be parents of young children and possibly breadwinners of extended families who are also among the most skilled within the population' [16] . In this respect, the long-term social impact of the AIDS epidemic could be compared with that of war or genocide. By weakening the country's most productive generation, AIDS and war leave economic, political and civil institutions significantly impaired: private industries are hamstrung by a lack of skills and productivity; state infrastructure is overwhelmed by the financial costs of coping and rebuilding; and a generation of children becomes the responsibility of impoverished communities or the state. As witnessed from the rates of infection from 1990 to 2004, a limited, prevention-only approach in South Africa has resulted in an estimated 5.4 million infections and more than a million deaths [17] . If war, genocide, or AIDS is left unrestrained long enough, the resulting devastation can take decades to recover from.
International responses: the case for treatment
The global nature of the HIV/AIDS epidemic has provided a wide array of data with which to evaluate international government responses. Variations in culture, societal institutions, working trends, and socioeconomic stratification, have led to differing rates of infection. When these elements are evaluated in the light of country-specific government policies, a series of meaningful comparisons emerges. South Africa's continuing rate of high HIV infection and death is fundamentally the result of inept government policy. Although significant and welcome progress has taken place in the last 3 months, the damage of the past is evident: denialism, pseudo-science and a dearth of political will have led to policies that are inconsistent and poorly implemented (if not actively detrimental), and have earned the South African Health Ministry scorn and embarrassment before the international health community. In 2002, when South Africa's Constitutional Court compelled the government to provide medicine to prevent mother-to-child transmission, the Court described the HIV/AIDS pandemic in terms that the government had only used in a pre-denialist time: it was 'an incomprehensible calamity', they stated, and 'the most important challenge facing South Africa since the birth of our new democracy' [18] . South Africa's inept leadership response separates it from AIDS epidemics in other southern African countries. Lesotho, Zambia, Mozambique and particularly Botswana have all benefited from greater AIDS leadership, despite a Prevention, treatment and care: lessons from South Africa Achmat and Simcock S13 shortage of infrastructure and fiscal and human resources. Even in neighboring Zimbabwe, denialism has not reared itself in the same manner as it has in South Africa; a fact made even more lamentable when we consider the high level of financial and infrastructural resources at our disposal.
Much has been written on why the South African government has resisted scaling up treatment. Although the evidence of AIDS denialism in South Africa is incontrovertible, the complexity of the origins and persistence of denialism require further investigation. What is clear is that the government promoted discredited, pseudo-scientific AIDS denialists, and provided them with government credibility. The result was a culture of AIDS denialism, and a set of practices that not only failed to reflect the scientific, medical or behavioural realities of the disease, but neglected to catalyse a sufficient sense of urgency in programmatic responses [3, [19] [20] [21] . In defense of government actions, some have suggested that given the existing burden on the state's health infrastructure and fiscal resources, there simply is not the capacity to provide nationwide ART. This line of thought has been refuted by evidence and by several leading scholars [22, 23] . Although the health system in South Africa is in need of support, and the costs of mitigating the HIVepidemic will be substantial (especially now that it may have reached potentially uncontrollable dimensions), there is no evidence to indicate that the provision of effective treatment and care is beyond the means of the state [23, 24] . It is almost certain, rather, that a failure to scale up prevention and treatment efforts, as envisaged by the South African Government's National Strategic Plan for 2007, will lead to the further destruction of the health system, and will worsen the costs for the state over the long term [25] . The scale-up of prevention and treatment is the only way to strengthen public healthcare systems that are currently under threat by AIDS. Laurie Garrett's recent article in Foreign Affairs: 'The Challenge of Global Health, February 2007', suggested that vertical investment in HIV/AIDS threatens public health systems in Africa. The author is a friend, but many of her assertions are misguided, wrong and dangerous. Unfortunately, the length and intended focus of our article preclude a full mention of the factual and logical errors in her piece. Paul Farmer's response was welcomed, but a thorough and complete rebuttal is needed.
Regardless of the rationale for the government's actions thus far, it is important to recognize the gains that have been made. In 2002, an extensive legal battle and significant grassroots mobilization enabled citizens to force the government to lift restrictions on access to nevirapine for preventing mother-to-child transmission [26, 27] . Important progress has been made since then. After country-wide protests in 2003 by the labour movement, faith-based bodies, organizations of women and children, the health profession and the scientific community with the Treatment Action Campaign (TAC), the government agreed to provide antiretroviral drugs at public health facilities. [28] .
Yet despite the availability of funding and the array of ongoing efforts, the number of individuals with untreated AIDS remains at over 500 000 [29] . Nationwide, the HIV-infected population is more than 5.4 million, and in 2006 new infections were estimated to be upwards of 520 000 [17] . South Africa's average life expectancy is now estimated at 51 years [30] .
The Brazilian government, by contrast, has endorsed a sustained and urgent policy framework to combat HIV/ AIDS. Although there are important differences between the epidemics in South Africa and Brazil, the instructive issue is that of leadership. In 1996, the Brazilian legislature granted free, universal access to ART, enabling all citizens to access medication and care, regardless of socioeconomic standing. The government also manufactured generic antiretroviral drugs to reduce costs, a decision that holds significant lessons for developing countries. In 2001, TAC and the Congress of South African Trade Unions sent a delegation to Brazil to draw attention to the abuse of patents by pharmaceutical companies.
The Brazilian Health Ministry paid careful attention to the groups most affected, extrapolating lessons learned to the wider population, and documenting the spread of the disease from major urban centres to more rural municipalities. The successful results of the policies are clear. Approximately 600 000 individuals in Brazil are currently estimated to be living with HIV, half the number the UN predicted a decade ago [7] . Historical evaluations suggest that the country's ART policy led to a 40-70% decrease in mortality, a 60-80% decrease in morbidity, and an 85% decrease in hospitalizations [31] . In S14 AIDS 2007, Vol 21 (suppl 4) 2004, the country's average life expectancy was reported to be as high as 71 years [32] . Figure 2 illustrates the difference in female death rates between Brazil and South Africa. In Brazil, the government has supported the combined approach of treatment and prevention for over a decade, whereas in South Africa, the government's prevailing approach has been prevention alone.
It is appropriate to pause here and mention that this comparison is intended for illustrative purposes. There are differences between the epidemics in these countries, including different structural risk and vulnerability, different patterns of male migrant labour, among others, and illustrative examples should not be over interpreted.
Nonetheless, the trends depicted in Fig. 2 are useful. The concept of the life lines is similar to the earlier illustration on South African death rates. The change in South African life patterns is also once again evident (only now depicting the female population alone, and on a proportional basis). The inclusion of the Brazilian life line, however, sheds light on the paramount importance of augmenting prevention efforts with effective treatment and care provision. The 'normal' look of the Brazilian curve is indicative of the negligible impact that the disease has had on women's life patterns. Free, widespread ART provision, a human rights-based prevention approach, and documentation of the programme's impact have enabled Brazil to keep a tight hold on the epidemic. In South Africa, the disease has encountered less resistance, resulting in the complete distortion of normal aging patterns.
Thailand provides another example of a developing country that has benefited from a well implemented, if 
Treatment investment and costs: South Africa's Western Cape province
The investment necessary to reduce and eradicate HIV transmission, as well as to reach and sustain universal access to HIV treatment, will be substantial. An honest and open costing assessment is the only manner in which to set realistic goals with achievable milestones. 'Thumb suck' estimates and a scarcity of modelling, which have plagued government forecasts in the past, will result in inadequate funding and will lead to ineffectual implementation and poor results. So far, the South African government has largely funded its entire HIV prevention and treatment programme independently. Contrary to many assumptions, the South African Treasury has consistently made money available for treatment. Delays in treatment have been the result of decisions by the Health Ministry and other government officials, rather than insufficient allocations of funding. Significant help from the Global Fund and PEPFAR has ensured more rapid access to treatment, but government investment remains the mainstay. Raising sufficient future resources will require prolonged political commitment on the part of the government and increased support from nongovernmental organizations and the private sector.
This year, the Government's National Strategic Plan for HIV/AIDS was accompanied by a costing analysis that outlined several scenarios for prevention and treatment. Assuming high adherence and 80% treatment coverage with ART, an outcome described in the plan as 'the high cost scenario', the total cost of prevention and treatment would escalate from almost 5 billion rand (US$725 million) in 2007 to 13.3 billion rand (US$1.93 billion) in 2011. This is a lower number than past treasury reports have predicted, a decrease that is probably the result of lower drug prices. The analysis emphasizes the role that mother-to-child-prevention efforts can play in saving future costs: 'It is noteworthy that the dual therapy PMTCT (prevention of mother-to-child transmission) programme and infant testing is only 4% of total costs. This is a highly cost-effective intervention, especially when one considers that it averts costs relating to the comprehensive care of HIV-positive children which is approximately 6% of the total. . .. If this programme was functioning properly, it would radically reduce paediatric AIDS cases' [33] .
The possibility for savings had been developed earlier by a team at the University of Cape Town's Centre for Social Science Research (some of whom were instrumental in developing the Government's National Strategic Plan) [23] . They suggested that although the funding increase needed to provide 80% or even 100%, ART delivery will be significant, it will be substantially offset by cost savings incurred through decreased hospitalization rates, and a reduction in opportunistic infections: 'The combined direct cost of the interventions (including treatment with ART, prevention efforts, and the treatment of opportunistic infections) at the peak of the epidemic (2015) is approximately R20 billion (including infrastructure and education costs). The savings in the expenditure to which the Government has legally committed itself (i.e. hospitalisation and orphan costs) would be a minimum of R7 billion' [23] . (The prices of many antiretroviral medications have dropped significantly since the time of these forecasts, which suggests that the numbers depicted here probably overestimate the costs necessary to provide universal treatment. Furthermore, the costing of opportunistic infections in the analysis was basic and probably underestimated the potential for cost savings in middle-income countries.) The analysis is careful to note that indirect socioeconomic benefits that result from increased ART provision have not been included, but would probably serve to mitigate the cost to the government further. These benefits include 'reduced sick-leave; higher productivity; fewer days taken off for employees to attend funerals; lower employee replacement costs' and the 'preservation of human capital' [23] .
The economic rationale to act with increased urgency is thus compelling. Paying now allows us to substantially mitigate the direct and indirect long-term costs of the epidemic. For example, the wide-scale provision of ART through primary care facilities would lessen the strain on the public health system in a number of dimensions.
Evidence from 2006 indicated that HIV-positive patients stayed in South African hospitals for an average of 13.7 days, compared with an 8.2-day average of HIV-negative patients. In district hospitals alone, the average stay for HIV-positive patients was four times greater than that of HIV-negative patients [34] . Often, increased public health expenditure and hospitalization time is the result of treating opportunistic infections. Studies have reported that the incidence of tuberculosis in AIDS patients is 500 times greater than that of the general population, suggesting that an HIV-positive individual is exponentially more likely to need public medical assistance. Antiretroviral drugs reduce the chances of an HIVinfected individual developing tuberculosis by up to 80%, thereby significantly reducing the likelihood that the individual will require further care [35] .
Again, HIV/AIDS damages the infrastructures and populations that are most needed to address it. AIDS mortality among healthcare workers places further strain on an underfunded, undersupported healthcare system. As indicated earlier, student nurses currently record one of the highest rates of HIV infection among any professional group in the country. Moreover, the training of new nurses is not keeping pace with demand, between 2000 and 2006, the South African Nursing Council registered 25 269 new nurses, but the number of those working in the public sector increased by only 6073; an average of only 1000 new public sector nurses each year [36] . The obvious irony here is that nurses, many of who are sick from AIDS, are critically needed to treat the large number of patients who are suffering from AIDSrelated illnesses.
With respect to drug pricing, South Africa continues to be hampered by the unreasonable and exorbitant costs of first-line antiretroviral medicines. Moreover, the costs of second-line regimens are up to 10 times higher than first-line regimens because there is no significant generic competition. It should be noted, however, that within the category of antiretroviral drugs, large discrepancies exist in drug pricing. The cost of Merck's efavirenz equated to 20% of the total treatment costs for patients in 2005. Sixty-four cents of every dollar allocated to adult first-line drug expenditure is spent on this drug alone [34] . Ultimately, therefore, the country's treatment costs remain high because drug costs remain high. South African private sector pricing continues to exceed generic alternatives in the majority of cases. International drug companies must desist in their fight against generic medications. In parallel, they must enter into an immediate agreement to license companies who are capable of producing quality generic medicines (especially antiretroviral drugs) with a royalty fee of 5% or less. If this fails, civil society and the government must then ensure that measures such as compulsory licenses are used.
Furthermore, increased resources should be allocated to obtaining fixed-dose combinations, with particular emphasis on providing the most durable first-line regimens available. First-line therapies are significantly less expensive than second-line therapies; patients who have access to the most effective and convenient first-line medications are much less likely to report resistance problems, or to struggle with adherence.
Finally, accuracy, as well as honesty, must be an integral component of the costing exercise. As indicated, the investment necessary to deliver widespread treatment and care will be substantial. But estimates of the number of individuals living with HIV must be based on legitimate, scientific forecasting methodologies. Roll-out plans must include detailed descriptions of staffing, including estimates of personnel needs and training procedures. When shortfalls exist, protocol should specifically describe how to enlist additional resources from the private sector.
Treatment outcomes and adherence: Western Cape province and Lusikisiki
Brazil and Thailand have demonstrated that prevention and treatment can reduce the incidence of new HIV infections and save lives. In South Africa's Western Cape province, clinicians at public hospitals have had access to antiretroviral drugs for their patients through a range of clinical trials since the late 1990s. In 2001, Médecins Sans Frontières started the internationally renowned treatment programme in Khayelitsha, the first treatment programme in community level public health facilities in the country. Since then, the outcomes data according to the provincial government suggest that, 'if anything, most of the modeling of treatment numbers have underestimated the potential impact of the intervention in our setting' [34] .
Despite the growing size of the AIDS epidemic in South Africa, as well as the high costs depicted above, South Africa's ART clinics have reported exceptional results. The costs are lower than anticipated, and the reduction in morbidities and mortality demonstrate that a public health approach to HIV treatment is feasible and necessary. Moreover, contrary to early scepticism, the country's adherence rates now rank among the highest in the world [34] . TAC and other organizations have employed a combination of treatment literacy techniques, as well as tailored, on-the-ground methods to increase community awareness. Treatment literacy coordinators and adherence counsellors make up the core of ART programming; these individuals use local knowledge of the community to increase awareness, inspire confidence in openness, and encourage consistency. Figure 3 portrays the high adherence rates achieved based on virological suppression in a sample of five public sector clinics within the Western Cape [37] . In the majority of patient groupings, adherence rates, based on whether or not a patient has missed treatment in the last 3 days, are well over 90%. Moreover, among treatment-naive
Prevention, treatment and care: lessons from South Africa Achmat and Simcock S17 patients who received treatment, over 90% achieve a viral load below 400 copies/ml at 6 months on ART. Finally, two important lessons have surfaced from early ART provision. First, primary care clinics continue to report greater access and adherence than secondary care clinics, while also saving costs for patients. For secondary clinics, the average travel time for patients is much greater than for those who have access to primary care, and for those not travelling by foot, the cost of transport is 14% higher than in primary care. Table 2 displays the difference in treatment results between primary care facilities ('clinics') and secondary care facilities ('hospitals').
As depicted, primary care clinics outperformed hospitals in virtually every dimension. Although the hospitals reported a lower death rate, this figure should be interpreted in the context of the much higher loss to follow-up rates that were recorded. Presumably some of the patients within this category who are no longer taking antiretroviral drugs may have died from AIDS-related complications.
The second lesson to be learned from early ART provision is that there is no difference in adherence rates or treatment successes in clinics staffed predominantly by nurses. Going forward, nurses can, and must, be given increased responsibility to roll out AIDS treatment and counselling. Their career paths, conditions of employment and remuneration must be developed to ensure that specialization and responsibility is valued at the primary care level. In Lusikisiki, all professional nurses have been trained to evaluate eligibility for ART and to monitor progress on ART: 'This is in keeping with the primary care principle that all services should be available at all times, avoiding a scenario in which service users must wait for a specific ''HIV day'' or a specific ''HIV nurse''. In fact, without this approach, clinic-based ART services would not have been possible as no extra people were employed to run HIV services in the clinics' [35] . As indicated earlier, the roles of community-based health workers, in the form of treatment literacy and adherence counsellors, have been indispensable. Investments in treatment literacy reduce costs through eliminating premature switching to second-line therapy and preventing the emergence of drug-resistant HIV. Through this and other means, community-based health workers add critical capacity, often taking on portions of the nurses' workload. Given the magnitude of South Africa's epidemic, they will be an important component of interventions going forward.
Assuming responsibility
Halting the spread of the HIV epidemic and providing universal treatment and care will require sustained longterm investment in healthcare and social security. Responsibility for this investment is, and will continue to be, a duty that must be shared.
Drug companies, governments and international organizations, including the World Bank, WHO and IMF, must negotiate the creation of a global mechanism to reward public and private research and development efforts, particularly those focused on HIV/AIDS, tuberculosis, malaria and neglected diseases. In parallel, they must ensure that intellectual property frameworks take full advantage of the stipulations of the Doha Declaration. Intergovernmental agencies must promote human rights-based, universal public health access and act with increased courage, daring and urgency based on the principle that everyone has an equal right to life, dignity and health. Drug companies should enter an immediate agreement voluntarily to license to any companies who satisfy the objective criteria necessary to produce quality generic medicines (especially antiretroviral drugs) with a royalty fee of 5% or less of the sale price, starting with a minimum of five licenses. Moreover, drug companies should work to ensure that critical drugs are fast-tracked through approval processes. To this end, international organizations and governments should provide unconditional support for the WHO prequalification process.
Finally, civil society, in partnership with governments and the private sector, must push for generic competition for all medicines (particularly antiretroviral drugs), as well as diagnostics. At a domestic level, we must promote and provide sustainable funding for treatment, prevention, literacy and advocacy; and, more broadly, advocate for the effective functioning of healthcare systems and the provision of quality healthcare for all sectors of society.
The combination of government revenue, private sector programmes, international assistance and contributions from wealthy households to treatment and prevention funding suggests that sharing the investment and the costs of HIV is the only sustainable way to address the epidemic. By contrast, not sharing the costs and failing to make the investments will result in unpredictable social dislocation that will affect the wealth and security of countries, companies and households. It can create political uncertainty, undermine economic growth, and spur a destructive social cycle catalysed by the devastation that the disease causes to individuals, families and communities. In South and southern Africa, the outlines of this tragedy, the individual and societal ramifications of AIDS, are manifest everywhere. Although noteworthy progress has been achieved through recent interventions, treatment provision has been slow to arrive, and it remains only a small component of what's necessary. Other countries have a duty to follow a different trajectory.
